|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mittal V: Epithelial mesenchymal
transition in aggressive lung cancers. Adv Exp Med Biol. 890:37–56.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tonetti M, Sturla L, Bisso A, Benatti U
and De Flora A: Synthesis of GDP-L-fucose by the human FX protein.
J Biol Chem. 271:27274–27279. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moriwaki K, Noda K, Nakagawa T, Asahi M,
Yoshihara H, Taniguchi N, Hayashi N and Miyoshi E: A high
expression of GDP-fucose transporter in hepatocellular carcinoma is
a key factor for increases in fucosylation. Glycobiology.
17:1311–1320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muinelo-Romay L, Villar-Portela S, Cuevas
Alvarez E, Gil-Martín E and Fernández-Briera A:
α(1,6)Fucosyltransferase expression is an independent prognostic
factor for disease-free survival in colorectal carcinoma. Hum
Pathol. 42:1740–1750. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang J, Kong P, Yang J, Jia Z, Hu X, Wang
Z, Cui H, Bi Y, Qian Y, Li H, et al: High TSTA3 expression as a
candidate biomarker for poor prognosis of patients with ESCC.
Technol Cancer Res Treat. 17:15330338187814052018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun Y, Liu X, Zhang Q, Mao X, Feng L, Su
P, Chen H, Guo Y and Jin F: Oncogenic potential of TSTA3 in breast
cancer and its regulation by the tumor suppressors miR-125a-5p and
miR-125b. Tumour Biol. 37:4963–4972. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rotunno M, Hu N, Su H, Wang C, Goldstein
AM, Bergen AW, Consonni D, Pesatori AC, Bertazzi PA, Wacholder S,
et al: A gene expression signature from peripheral whole blood for
stage I lung adenocarcinoma. Cancer Prev Res (Phila). 4:1599–1608.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kong W, Zhao JJ, He L and Cheng JQ:
Strategies for profiling microRNA expression. J Cell Physiol.
218:22–25. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaikkonen MU, Lam MT and Glass CK:
Non-coding RNAs as regulators of gene expression and epigenetics.
Cardiovasc Res. 90:430–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Janga SC and Vallabhaneni S: MicroRNAs as
post-transcriptional machines and their interplay with cellular
networks. Adv Exp Med Biol. 722:59–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Ma Y, Liu C, Li P and Yu T: Reduced
miR-125a-5p level in non-small-cell lung cancer is associated with
tumour progression. Open Biol. 8:82018. View Article : Google Scholar
|
|
16
|
Zhong L, Sun S, Shi J, Cao F, Han X and
Chen Z: MicroRNA-125a-5p plays a role as a tumor suppressor in lung
carcinoma cells by directly targeting STAT3. Tumour Biol.
39:10104283176975792017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong X, Zhao Y, Li X, Tao Z, Hou M and Ma
H: Overexpression of HIF-2alpha-Dependent NEAT1 promotes the
progression of non-small cell lung cancer through
miR-101-3p/SOX9/Wnt/beta-catenin signal pathway. Cell Physiol
Biochem. 52:368–381. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sebio A, Kahn M and Lenz HJ: The potential
of targeting Wnt/β-catenin in colon cancer. Expert Opin Ther
Targets. 18:611–615. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yue B, Liu C, Sun H, Liu M, Song C, Cui R,
Qiu S and Zhong M: A positive feed-forward loop between
LncRNA-CYTOR and Wnt/beta-catenin signaling promotes metastasis of
colon cancer. Mol Ther. 26:1287–1298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arce L, Yokoyama NN and Waterman ML:
Diversity of LEF/TCF action in development and disease. Oncogene.
25:7492–7504. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang S, Li Y, Wu Y, Shi K, Bing L and Hao
J: Wnt/β-catenin signaling pathway upregulates c-Myc expression to
promote cell proliferation of P19 teratocarcinoma cells. Anat Rec
(Hoboken). 295:2104–2113. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woodard GA, Jones KD and Jablons DM: Lung
cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Taparra K, Wang H, Malek R, Lafargue A,
Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, et
al: O-GlcNAcylation is required for mutant KRAS-induced lung
tumorigenesis. J Clin Invest. 128:4924–4937. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimizu M and Tanaka N: IL-8-induced
O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem
cell-like properties in colon and lung cancer cells. Oncogene.
38:1520–1533. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kizuka Y, Nakano M, Yamaguchi Y, Nakajima
K, Oka R, Sato K, Ren CT, Hsu TL, Wong CH and Taniguchi N: An
alkynyl-fucose halts hepatoma cell migration and invasion by
inhibiting GDP-fucose-synthesizing enzyme FX, TSTA3. Cell Chem
Biol. 24:1467–1478.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan S, Brentnall TA and Chen R:
Glycoproteins and glycoproteomics in pancreatic cancer. World J
Gastroenterol. 22:9288–9299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Villar-Portela S, Muinelo-Romay L, Cuevas
E, Gil-Martín E and Fernández-Briera A: FX enzyme and GDP-L-Fuc
transporter expression in colorectal cancer. Histopathology.
63:174–186. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Niittymaki J, Mattila P and Renkonen R:
Differential gene expression of GDP-L-fucose-synthesizing enzymes,
GDP-fucose transporter and fucosyltransferase VII. APMIS.
114:539–548. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Noda K, Miyoshi E, Gu J, Gao CX, Nakahara
S, Kitada T, Honke K, Suzuki K, Yoshihara H, Yoshikawa K, et al:
Relationship between elevated FX expression and increased
production of GDP-L-fucose, a common donor substrate for
fucosylation in human hepatocellular carcinoma and hepatoma cell
lines. Cancer Res. 63:6282–6289. 2003.PubMed/NCBI
|
|
33
|
Naidu S, Shi L, Magee P, Middleton JD,
Laganá A, Sahoo S, Leong HS, Galvin M, Frese K, Dive C, et al:
PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung
tumorigenesis by targeting multiple components of KRAS and NF-κB
pathways. Sci Rep. 7:154412017. View Article : Google Scholar : PubMed/NCBI
|
